stockrowPfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
- Revenue
- −0.43%
- EPS
- −7.98%
- Free cash flow
- +20.0%
- Total debt
- +1.55%
Quarter to September 2026, against a year earlier
Follow PFE
Alert me
Pfizer Inc. (PFE) Revenue growth
Pfizer Inc.'s revenue growth over the twelve months to 30 September 2026 was 1.34%, up 3.0 percentage points from fiscal 2025 (−1.65%). Over the past ten years it has ranged from −41.1% (fiscal 2023) to 95.2% (fiscal 2021); the current reading is higher than 27% of that period. That is below the Drug Manufacturers General industry median of 6.72% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | −1.65% | (8.49) |
| FY2024 | 6.84% | 47.98 |
| FY2023 | −41.1% | (65.60) |
| FY2022 | 24.5% | (70.70) |
| FY2021 | 95.2% | 93.34 |
| FY2020 | 1.82% | 1.62 |
| FY2019 | 0.20% | 22.51 |
| FY2018 | −22.3% | (21.78) |
| FY2017 | −0.53% | (8.66) |
| FY2016 | 8.13% | 9.65 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | −0.43% | (3.03) |
| Jun 2026 | 2.60% | (2.77) |
| Mar 2026 | 5.37% | 6.53 |
| Dec 2025 | −1.16% | 4.76 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| SNY Sanofi compare | 26.3% |
| NVO Novo Nordisk A/S compare | 13.2% |
| AMGN Amgen Inc. compare | 8.15% |
| AZN AstraZeneca PLC compare | 7.32% |
| GSK GSK PLC Sponsored ADR compare | 6.90% |
| GILD Gilead Sciences, Inc. compare | 6.54% |
| BMY Bristol Myers Squibb Company compare | 4.16% |
| NVS Novartis AG compare | 1.76% |
| PFE Pfizer Inc. | 1.34% |
| Drug Manufacturers General industry median | 6.72% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on PFE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement